OC
SPRY icon

Oppenheimer & Co’s ARS Pharmaceuticals SPRY Stock Holding History

Oppenheimer & Co’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.9K Sell
12,439
-5,419
-30% -$51.9K ﹤0.01% 1643
2025
Q4 		$208K Buy
17,858
+5,344
+43% +$52K ﹤0.01% 1421
2025
Q3 		$126K Hold
12,514
– – ﹤0.01% 1595
2025
Q2 		$218K Sell
12,514
-2,500
-17% -$36.1K ﹤0.01% 1471
2025
Q1 		$189K Buy
+15,014
New +$181K ﹤0.01% 1467

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Oppenheimer & Co's SPRY Position: Q1 2026 in Review

Oppenheimer & Co reduced its ARS Pharmaceuticals (SPRY) stake by 30% in Q1 2026, selling an estimated $51.9K and leaving 12,439 shares worth $99.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

Oppenheimer & Co first reported a position in SPRY in Q1 2025 and has held it in 5 quarters since. The position peaked at $218K in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Oppenheimer & Co held 12,439 shares of ARS Pharmaceuticals worth $99.9K as of Q1 2026.
  • Oppenheimer & Co sold 5,419 ARS Pharmaceuticals shares in Q1 2026, an estimated $51.9K.
  • ARS Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1643 holding.
  • Oppenheimer & Co first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Oppenheimer & Co's ARS Pharmaceuticals position peaked at $218K in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.